Akash Tewari
Stock Analyst at Jefferies
(2.82)
# 1,641
Out of 5,182 analysts
65
Total ratings
44.9%
Success rate
7.59%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $151 → $138 | $91.18 | +51.35% | 4 | Mar 10, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiates: Buy | $580 | $438.71 | +32.21% | 1 | Mar 10, 2026 | |
| AMGN Amgen | Initiates: Hold | $350 | $347.94 | +0.59% | 1 | Mar 10, 2026 | |
| GILD Gilead Sciences | Initiates: Buy | $180 | $139.71 | +28.84% | 1 | Mar 10, 2026 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $52.72 | -33.61% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $74.79 | +28.36% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $761.85 | +9.08% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $19.40 | +34.02% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $10.85 | -7.83% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $59.60 | +14.09% | 4 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $55.50 | +71.17% | 2 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 → $16 | $12.54 | +27.59% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $177 → $189 | $131.60 | +43.62% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $40.41 | +97.97% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $935.58 | +8.49% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $34.84 | +43.51% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $84.34 | -11.07% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $47.58 | -34.85% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $28.32 | +37.71% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $13.14 | +36.99% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $746.75 | -31.30% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $120.87 | +3.42% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $25.80 | -57.36% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.52 | +1,018.42% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $66.73 | +12.39% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $546.89 | -72.39% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $43.88 | -36.19% | 3 | Oct 7, 2021 |
BioNTech SE
Mar 10, 2026
Maintains: Buy
Price Target: $151 → $138
Current: $91.18
Upside: +51.35%
Vertex Pharmaceuticals
Mar 10, 2026
Initiates: Buy
Price Target: $580
Current: $438.71
Upside: +32.21%
Amgen
Mar 10, 2026
Initiates: Hold
Price Target: $350
Current: $347.94
Upside: +0.59%
Gilead Sciences
Mar 10, 2026
Initiates: Buy
Price Target: $180
Current: $139.71
Upside: +28.84%
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $52.72
Upside: -33.61%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $74.79
Upside: +28.36%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $761.85
Upside: +9.08%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $19.40
Upside: +34.02%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $10.85
Upside: -7.83%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $59.60
Upside: +14.09%
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $55.50
Upside: +71.17%
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $12.54
Upside: +27.59%
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $131.60
Upside: +43.62%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $40.41
Upside: +97.97%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $935.58
Upside: +8.49%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $34.84
Upside: +43.51%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $84.34
Upside: -11.07%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $47.58
Upside: -34.85%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $28.32
Upside: +37.71%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $13.14
Upside: +36.99%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $746.75
Upside: -31.30%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $120.87
Upside: +3.42%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $25.80
Upside: -57.36%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.52
Upside: +1,018.42%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $66.73
Upside: +12.39%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $546.89
Upside: -72.39%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $43.88
Upside: -36.19%